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 Résumé 
 
Objectifs  
Le Nystatin est un antibiotique efficace pour le traitement d’otomycose. Bien que sa 
sécurité au niveau de l’oreille externe soit bien établie, son utilisation n’est pas 
recommandée lorsqu’il y a une perforation tympanique. L’objectif de cette étude est 
d’évaluer le potentiel ototoxique du Nystatin lorsque celui-ci est appliqué directement au 
niveau de l’oreille moyenne.  
Méthodes  
Nous avons fait une étude expérimentale avec 18 cochons d’Indes de souche Hartley que 
nous avons divisés en deux groupes. En exposant l’oreille moyenne de chaque animal au 
Nystatin (groupe I) ou à la néomycine (groupe II) et chaque oreille controlatérale à une 
solution physiologique (NaCl), la fonction auditive a été évaluée avec un test de 
potentiels évoqués auditif du tronc cérébral avant et après les injections. Une étude par 
microscopie électronique a permis une comparaison histologique de l’état des cellules 
ciliées cochléaires entre les 2 groupes. 
Résultats 
Les pertes auditives moyennes du groupe « Nystatin » étaient de 13.0 dB et comparables 
aux pertes moyennes observées dans les oreilles ayant été injectées avec du NaCl (4.0 dB 
dans le groupe I et 15.1 dB dans le groupe II).  Le groupe de contrôle « néomycine » a 
subi une perte auditive moyenne de 39.3 dB, ce qui représente une différence 
cliniquement et statistiquement significative (p<0.001). L’étude histologique avec une 
microscopie à balayage électronique a démontré une conservation de l’architecture des 
cellules ciliées cochléaires dans les groupe Nystatin et NaCl. La néomycine a causé une 
destruction marquée de ces structures. 
Conclusions  
Le Nystatin ne provoque pas d’atteinte auditive ni de destruction des cellules ciliées 
externes après injection directe dans l’oreille moyenne chez le cochon d’Inde.  
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Abstract 
Objective 
Nystatin is an effective topical antifungal agent widely used in the treatment of 
otomycosis. Though it is safe for external ear use, current recommendations are to avoid 
its use in cases of tympanic membrane perforation. The objective of our study was to test 
the security of Nystatin when applied directly to the middle ear of a guinea pig model. 
Methods 
We performed an experimental study with 18 Hartley guinea pigs that were divided into 
two groups. Exposing middle ears from one group to Nystatin (group I) and from the 
other to the ototoxic neomycin (group II), we compared results of auditory brainstem 
response (ABR) testing at three intervals during the study.  Each animal’s contralateral 
ear was injected with a physiological solution (NaCl). At the end of the study, we 
performed a histological analysis of the animals’ cochleae using a scanning electron 
microscope. 
Results 
Average hearing loss in the Nystatin group was 13.0 dB which was similar to the results 
obtained in the NaCl-exposed ears (4.0 dB in group I and 15.1 dB in group II). Average 
hearing loss in the neomycin group was 39.3 dB, which represents a clinically significant 
difference (p<0.001). Scanning electron microscope evaluation revealed intact cochlear 
hair cell architecture in the Nystatin and normal saline groups, compared to important 
destruction in the neomycin group. 
Conclusion 
Nystatin does not cause hearing impairment or cochlear hair cell damage when exposed 
directly to the middle ear of a guinea pig model.  
 
Key words : Otomycose, Nystatin, Neomycin, ototoxicity, middle ear, hair cells 
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Introduction 
 
Otomycosis is a common pathology among children and adults. Initially defined as 
fungal infection of the external ear, this definition has evolved in recent years to include 
infection extending to the middle ear and open mastoid cavities(1). This type of infection 
has been associated with chronic otitis media(2). Some suggest that a recent increase in the 
prevalence of otomycosis is due to increasing use of topical quinolones, which increase risk 
of opportunistic infection. 
 Like with other fungal infections, exposure to a hot and humid environment is an 
important risk factor.  Common presentation includes unilateral ear pain with persistent 
discharge and mild hearing loss. Physical examination reveals a typical white crust lining 
the outer ear. When culture is performed, Candida albicans, Candida parapsilosis and 
Aspergillus fumigatus are the pathogens found in over 95% of cases(3). Proper treatment 
requires keeping the ear sufficiently dry and application of a local topical antifungal cream 
or ointment. 
 Studies measuring the safety of these agents in animal models have yielded mixed 
results. Acetic acid and gentian violet have demonstrated a potential for ototoxicity (4, 5). 
Other common agents including clotrimazole, ciclopirox and miconazole had no deleterious 
effect on cochlear outer hair cell architecture(5-7). 
In 2000, Tom performed an experiment using electron microscopy to study the 
effect of several known anti-mycotic agents on guinea pig outer hair cell (OHC) structure(5). 
Though he was able to prove histologically an absence of toxicity from clotrimazole,  
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miconazone and tolnaftate, no conclusive results were obtained with regards to Nystatin. 
Furthermore, no correlation between histological analysis and auditory brainstem response 
(ABR) was made. 
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Objective 
 
The objective of this study is to evaluate the toxic potential of Nystatin when 
applied directly into the middle ear of an animal model. In order to do so, we have 
performed the first study evaluating the effect of Nystatin on both the microscopic integrity 
of the OHCs of their cochlea and the results obtained on ABR evaluation. 
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Review of the literature 
 
Anatomy and Physiology 
 An in-depth understanding of the anatomy and physiology of the auditory system is 
essential for such a project to be successful. A brief overview of the key concepts will be 
discussed here, with specific emphasis on ABR. 
 Before reaching the inner ear, a sound wave must travel through the external ear, the 
middle ear with its three ossicles and the oval window(8). Each of these structures has a 
specific role in sound amplification.  
 The external ear is composed of the auricle, the external auditory canal and the 
tympanic membrane. These structures combine to amplify sound by a factor of 30 to 100 at 
3000 Hz(9). They also serve as a frequency filter, helping with sound localization since 
sources located at a higher location transmit high frequencies more readily. 
 The middle ear allows a transition from a low-impedance environment (air) to a 
high-impedance environment (fluid). This situation would normally result in a reflection of 
99% of sound energy, but the middle ear compensates with two separate mechanisms. First 
and foremost, the large surface area of the tympanic membrane vibrates and concentrates its 
energy on the relatively small surface area of the oval window, increasing the amplitude by 
a factor of 17-20. Second, the lever effect created by the ossicles creates a slight amplitude 
gain (about 1.3 times)(10). 
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Figure 1: Transverse section of the cochlea 
 
 Source: 1997 Encyclopaedia Britannica, Inc. 
The principal acoustic structure of the inner ear, the cochlea, has three functions: 
sound amplification, breakdown of complex acoustic waves into simpler ones, and 
conversion of sound waves into nerve effluxes. The cochlea is divided into three 
compartments, as shown on the transverse section of Figure 1. Note the basilar membrane, 
which separates the scala tympani from the cochlear duct. Also shown is the organ of Corti, 
the neurosensory unit of hearing, composed mainly of the tectorial membrane and inner and  
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outer hair cells. When the stapes vibrates, it causes a movement of footplate in the oval 
window and an increase in the pressure of the perilymph of the scala vestibuli. This 
pressure gradient is transmitted to the scala tympani via a communication at the cochlea’s 
apex, the helicotrema. From this point, a vibration of the basilar membrane instigates an 
approximation of the tectorial membrane to the hair cells. This begins the process known as 
sound transduction. Each section of the cochlea is responsible for sound transduction for a 
specific frequency, with low frequencies at the apex and high frequencies at the base. This 
tonotopic organization is maintained throughout the auditory pathway culminating in the 
primary auditory cortex. 
 Neural input leaves the cochlea via the cochlear nerve. The great majority (95%) of 
the nerve fibers that make up the cochlear nerve origin from the single row of inner hair 
cells, whereas the rest origin from the three rows of OHCs. The auditory nerve pathway 
continues toward the cochlear nucleus, the superior olivary nuclei, the lateral lemniscus and 
the inferior colliculus of the midbrain before reaching its terminal fibers in the acoustic area 
of the temporal lobe cortex(11). This pathway is the subject of testing when performing ABR 
tests. This clinical exam measures electrical activity along the auditory pathway using 
earphones and strategically placed electrodes. This exam does not require patient 
collaboration, making it ideal for testing in young children and animals. Hearing thresholds 
are determined mainly by identifying reproducible I, III, and V waves on two or more 
occasions beyond a reasonable doubt. These three waves measure activity in the distal 
cochlear nerve, the superior olivary complex, and the inferior colliculus, respectively(12). 
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Guinea pigs: 
Most studies researching ototoxic agents are performed on animals. Though mice, 
rats and chinchillas have all been studied, guinea pigs are the most popular choice among 
researchers owing to their readily accessible round window niche (RWN). It is worth 
underlining some of the anatomical and physiological differences found between human 
and guinea pig auditory systems. 
The inner ear anatomy of the guinea pig resembles that of a human with a few 
notable differences. In 2005, Wysocki reviewed the topographical anatomy of the guinea 
pig temporal bone(13). The three most important specific characteristics of the cochlea were 
its 3.5 turns, its thin bony cover and the unique position of the round window. Despite a 
study by Counter using magnetic resonance imaging claiming a guinea pig cochlea has 2.5 
turns, Wysocki supported the popular belief that it actually ranges from 3.5 to 4 turns(14-17). 
The thin bony cover is found in all rodent species, in great contrast to human anatomy. 
Finally, the round window is found in the posterio-superior end of the basal turn of the 
cochlea. Although this finding does not have physiological implications, it makes access to 
the cochlea via the middle ear much easier in the setting of an experimental study. 
 Perhaps the most important functional difference between the two species is their 
hearing range. While humans can hear sound ranging from 20 to 20 000 Hz, guinea pigs 
have been shown in behavioral studies to respond to sounds up to 50 000 Hz(18). There 
appears to be a relationship between this finding and the extra turn of the cochlea. Studying 
several different animal species, West successfully demonstrated a statistically significant 
positive correlation between number of turns of the cochlea and length of the basilar  
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membrane with the range of audible frequencies(19). In low frequencies, however, guinea 
pigs are less sensitive. In a 2010 review Salt found that average hearing thresholds at 125 
dB were 17.6 dB higher than the human average(20). 
Despite these differences, humans and guinea pigs appear to respond similarly to 
known ototoxic agents. Blakley found dose-dependent hearing loss after Cisplatin treatment 
in guinea pigs comparable to levels reported in the literature for humans(21). Of the studies 
discussed in this paper, none have found major discrepancies between human and guinea 
pig response to ototoxic drugs. 
  
Antibiotic Ototoxicity 
 Ototoxicity to antibiotic agents is not a new concept. Soon after gaining popularity 
in the early 1940’s, systemic gentamicin appeared to be responsible for permanent bilateral 
hearing loss with or without vestibular defects in a significant number of treated patients(22). 
Since that time, several studies have tested commonly used antibiotics for their potential 
short and long-term effects on hearing. For the purposes of this review, antibacterial agents 
will be discussed first followed by an in-depth look at anti-mycotic agents. 
 Aminoglycosides are bacteriostatic agents that exert their effect by inhibiting the 
30S ribosomal subunits of targeted pathogens. Soon after an association between 
gentamicin treatment and hearing loss was established, cochlear hair cell damage was 
discovered on histological analysis. Further testing demonstrated intracochlear gentamicin 
concentrations were similar to systemic concentrations, but that the antibiotic was 
sequestered in the inner ear with a half life of up to 5 months(23). It appears to generate free 
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radicals which damage inner ear neurons, resulting in irreversible hearing loss(24). Recent 
studies have shown that hair cells at the base of the cochlea are affected before those at the 
apex, explaining why resulting hearing loss in worst in high frequencies(25). Severe toxicity 
can also cause retrograde auditory nerve damage. This effect is dose-dependent and can be 
worsened by age or in combination with other ototoxic treatments such as loop diuretics. 
Other aminoglycosides appear to be just as harmful. Despite one study suggesting its 
safety(26), neomycin has proven ototoxic potential and should be avoided when possible(5, 
27). While amikacin, kanamycin and neomycin have an important propensity for 
cochleotoxicity, streptomycin appears to have more vestibulotoxic properties(28). In a study 
by Song et al., iron chelators seemed to have protective properties with the use of 
gentamicin(29). Further evidence should be obtained, however, before such a treatment can 
be considered safe. Though efforts continue to find effective protective agents against 
aminoglycoside ototoxicity(25), for the moment it is best to limit long-term use of these 
agents whenever possible.  
 The obvious deleterious effects of aminoglycosides have led researchers to 
investigate the possible consequences of other antibiotics, notably ones used for local 
treatment of otitis externa. Fluoroquinolones have proven their safety in a large number of 
studies. Topical ciprofloxacin does not cause significant damage to cochlear hair cells(30-35). 
This is presumably because the molecule does not diffuse across the cochlear round 
window membrane even when applied directly into the middle ear space(36). Among topical 
quinolones, only moxifloxacin has demonstrated a potential for cochleotoxicity(37), 
although this study was performed exclusively using distortion product oto-acoustic 
emissions and results have not been duplicated.  
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Antimycotic agents have been studied with great interest owing to the increasing 
worldwide rate of otomycosis. In 1974, Schonebeack and Zakrisson were the first to study 
the possibility of ototoxic antimycotics(38). They published a case report of two patients 
treated with 5-fluorocytosine and performed post-treatment audiograms, which were 
normal. Since that time, studies have greatly evolved. In order to test the effects of 
Nystatin, amphoterecin B, and Griseofulvin, Parker and James performed a standard 
microscopic evaluation of guinea pig cochleas treated with these agents(39). They concluded 
that while Nystatin and amphoterecin B seemed safe, Griseofulvin altered OHC 
architecture. Spandow was the first to utilize ABR testing post-antifungal treatment, finding 
a significant hearing loss in rats after gentian violet administration(40). Based on clinical 
symptoms in a prospective study of 411 patients, Paulose found no ototoxic reactions after 
topical treatments with clotrimazole, Nystatin and econazole(1). In an experimental guinea 
pig study using ABR testing, Marsh and Tom found solutions containing acetic acid and 
propylene glycol to be harmful. Clotrimazole and tolnaftate, on the other hand, had little or 
no impact on auditory thresholds(7). As a follow-up to this study, Tom used scanning 
electron microscopy (SEM) to verify the state of OHCs after exposure to six well-known 
agents(5). As expected, clotrimazole, miconazole and tolnaftate proved safe and gentian 
violet caused OHC destruction. Nysatin left an apparent residue in the cochlea impeding 
proper evaluation, which led the author to suggest avoiding Nystatin in cases of tympanic 
membrane perforation. Jinn reported modified OHC morphology and decreased time to cell 
death in guinea pig cochleas exposed to acetic acid, confirming earlier findings(4).  Most 
recently, in 2008, Baylancicek found no significant impact of Ciclopirox treatment on ABR 
testing in guinea pigs(6). Table 1 summarizes our antibiotic ototoxicity literature review. 
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Table 1: Antibiotic Ototoxicity Literature Review 
Author Year Molecule Study Design Subjets Number ABR Microscopy 
Kavanagh et al. 2009 Cipro-Dexa Experimental Mice 12 Yes No 
Baylancicek et al. 2008 Ciclopirox Experimental Guinea 
Pigs 
22 Yes No 
Daniel et al. 2008 Cipro-Dexa Experimental Chinchilla 15 Yes Yes 
Daniel et al. 2007 Moxifloxacin Experimental Chinchilla 20 OAE No 
Macfadyen et al. 2006 Many Review Human 833 No No 
Thomas et al. 2005 Tri-Adcortyl Case Report Human 1 No No 
Suzuki et al. 2003 Olfloxacin Prospective 
observational 
Humans 294 No No 
Migirov et al. 2003 Ciloxan, 
Garamycin 
Experimental Guinea 
Pigs 
35 OAE No 
Becvarovski et al. 2002 Cipro Experimental Humans 10 No No 
Hurst et al. 2001 Clotrimazole Prospective 
observational 
Humans 22 No Direct 
Russell et al. 2001 Cortisporin, 
Cipro HC, 
Ciloxan, 
Floxin 
Experimental Chinchilla 
(in vitro) 
? No Electron 
Garcia et al. 2001 Many Review Animals - - - 
Tom 2000 Clotrimazole, 
miconazole, 
Nystatin 
Tolnafate, 
gentian violet 
Experimental Guinea 
Pigs 
10 each No Yes 
Ohki et al. 2000 Fluconazole Case Report Human 1 No No 
Ikiz et al. 1999 Cipro Experimental Guinea 
Pigs 
11 Yes No 
Song et al. 1997 Gentamycin Experimental Guinea 
Pigs 
32 Yes No 
Mayer et al. 1994 Amphoterecin 
B 
Case Report Human 1 No Direct 
Barlow et al. 1994 Cortisporin, 
Gentamycin, 
benzalkonium, 
olfloxacin 
Experimental Guinea 
Pigs 
15 each No Electron 
Brownlee et al. 1992 Cipro Experimental Guinea 
Pigs 
35 Yes No 
Claes et al. 1991 Cipro Experimental Guinea 
Pigs 
30 Yes No 
Marsh and Tom 1989 Cresylate, 
Vosol, 
Clotrimazole, 
Tolnaftate 
Experimental Guinea 
Pigs 
3 each Yes No 
Paulose et al. 1989 Clotrimazole, 
Nystatin, 
econazole 
Prospective Humans 411 No No 
Spandow et al. 1988 Gentian Violet Expertimental Rats Unknwown Yes No 
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Parker and James 1978 Nystatin etc. Experimental Guinea 
Pigs 
6 to 8 No Yes 
Stone et al. 1975  Systemic 
Tobramycin 
RCT Humans 116 No No 
Schonebeck and 
Zakrisson 
1974 5-
fluorocytosine 
Case Report Humans 2 No No 
 
Inner Ear Evaluation 
 Testing inner ear function in an animal model is challenging, and each technique 
has its advantages and drawbacks. Here we will briefly review four well-described 
techniques: cochleogram plotting, SEM, otoacoustic emissions (OAE) and ABR.  
Early studies used contrast microscopy to establish a mapping of apparent cochlear 
hair cell damage named a cochleogram(39). This technique has the benefit of studying the 
entire cochlear structure, thereby comparing basal and apical cell damage. Although this 
technique has been used in experimental studies since 1966, only recently has a review 
been published with a proposed standardized cochleogram technique(41). The authors 
suggest plotting basilar membrane length as a percent instead of a length, stating equations 
used for frequency-place maps and normalizing different basilar membrane lengths to 
percentaged before making average cochleograms. There are several limitations to this 
technique. First, no clear correlation has been demonstrated  between electrocochleogram 
findings and frequency-specific hearing evaluation. Second, it is a technically difficult 
procedure due to tectorial membrance adhesion, which often limits the view of a significant 
portion of cochlear hair cells.  
With the availability of SEM, preservation of cochlear hair cell architecture and the 
length of the basilar membrane are now used to evaluate potential damage(42). Basilar 
membrane length should be standardized and expressed as a percentage rather than a 
length(41). The limitations of this technique are twofold. First, proper visualisation of the 
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entire cochlear ramp and its inner and outer hair cells is extremely challenging. Details 
on cochlear dissection and preparation have been described elsewhere(43). Second, the 
results obtained are purely histological and may not accurately reflect in vivo  inner ear 
function.  
Two techniques are potentially effective in measuring inner ear function in an 
animal model. Oto-acoustic emissions are the easiest and fastest to perform, and have been 
used in a number of studies(44-51). Their reliability has been challenged in a study by 
Migirov et al., who found similar distortion products in guinea pigs treated with normal 
saline and topical gentamicin(44). He argues that results reflect the degree of inflammation 
of the middle ear more than actual inner ear function.  
Auditory brainstem response is a more complex yet potentially more reliable and 
widely-used measure of animal inner ear function(6, 30-32, 34, 52-71). We recommend a 
combination of ABR and electron microscopy to correlate functional status with 
histological analysis. A recent study using these techniques demonstrated the protective 
effect of Ringer’s Lactate solution in guinea pigs who receive Cisplatin compared to a 
control group(72). 
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Methods 
 
Animals 
We used a total of 18 Hartley Guinea Pigs. We chose this species because of their 
readily accessible cochlea, their functional anatomy which resembles that of humans, their 
widespread use in similar studies and finally because of our significant experience with this 
species in our laboratory. 
Animals were cared for in accordance with the guidelines of the Canadian Council 
of Animal Care and the standards of the institutional animal care committee.  
 
General Procedures and Group Assignment 
The experiment was performed over a span of 13 weeks, beginning with group 
assignation and ending with SEM interpretation.  
Each guinea pig was randomly assigned to one of two groups: an experimental 
group (Group I) and a positive control group (Group II). Animals from Group I received 
Nystatin injections in one randomly selected ear and physiological saline (0.9% NaCl) 
injections in the other. Animals from Group II received neomycin injections in one ear and 
physiological saline in the other. Each contralateral ear was therefore used as a negative 
control, which allowed us to reduce the number of animals required and minimize the effect 
of variability between animals. 
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Anesthesia protocol 
Anesthesia was induced by placing the animals in a plastic container with two 
entrance ports and one exit port. Oxygen and Isoflurane 1% were administered in parallel 
systems and were ventilated out through the exit port. All manipulations, including 
tympanic membrane (TM) perforation, middle ear injections, and animal sacrifice were 
performed under general anesthesia. The guinea pigs had spontaneous breathing but did not 
react to stimulus. ABR recordings required us to maintain anesthesia with a mask outside of 
the container. Each animal’s adequate recovery from anesthesia was assured before leaving 
it unsupervised. 
 
Tympanic Membrane Perforation and Injection 
On Day 1 of the experiment, we perforated the posterior superior quadrant of each 
TM under general anesthesia using an operative microscope. Approximately 60% of the 
surface of the TM was left intact in each case. This perforation provided an adequate 
exposure of the round window niche (RWN), where the assigned product would later be 
applied. Each animal then passed an ABR test within the first week. ABR protocol details 
are described below. 
 On Day 5, we injected approximately 0.1 cc of the experimental solution into each 
ear. The injection was performed through the perforation using a long 20-gauge needle. The 
solution was deposited directly over the round window niche and filled the entire middle 
ear cavity. A concern for the animals in Group II was that the neomycin, since it is a liquid 
and much less consistent than Nystatin, would not remain in the middle ear long enough to 
exert an effect. We therefore added 0.1 cc of Neosporin 0.25% cream to emulate the  
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conditions in Group I. Each injection as described above was repeated once a week for a 
total of three weeks. 
 At this point we waited a total of four weeks before proceeding with further tests. 
This waiting time was considered necessary in order to minimize the amount of residue 
present at the RWN, which if considerable could interfere with ABR readings as well as 
SEM analysis. 
 Our second ABR recordings were performed during week 8. A thorough cleaning 
and drying of each ear was performed the day before the recordings. The tympanic 
membrane was reperforated in the ears if closure had occurred.  
 Because the first set of injections did not cause adequate hearing loss as 
demonstrated by ABR results in the positive control neomycin group (group II), we 
repeated a series of three injections in each group at closer intervals (48 hours between 
injections). Four weeks later, we repeated all ABR testing. 
 
Table 2: Description of Injection Materials 
Drug Manufacturer Concentration Type 
Nystatin Ratiopharm 100 000 U/g Ointment 
Neomycin Ratiopharm 1% Aqueous 
Neosporin GlaxoSmithKline 0.25% Cream 
NaCl - 0.90% Aqueous 
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Auditory Brainstem Response 
 All ABR tests were performed with the same Nicolet Bravo™ device (Nicolet Bravo 
System; Nicolet Biomedical, Madison, WI, USA). The same room of the animal care center 
was used for all tests. Electrodes were inserted subcutaneously. The non-inverting 
electrodes were placed directly above the left and right mastoid processes, the inverting 
electrode was placed at the apex and the ground electrode was placed in the middle of the 
animal’s back. 
 We used tone burst stimuli to record differences across a range of frequencies. Tone 
bursts at 2000, 3000, 4000, 6000 and 8000 Hz were emitted. Amplitude thresholds were 
found to the nearest 5 dB. A minimum of 300 repetitions were averaged out with each 
recording. To be considered a positive reading, a visible wave V needed to be reproducible 
beyond a doubt on a minimum of two stimulations with the same amplitude. ABR values 
are provided as absolute decibel (dB) levels. 
Animal Sacrifice and Preparation 
 All animals were sacrificed under general anesthesia. For initial dissection we 
focused on exposing the middle ear by removing the residual TM and the cartilaginous 
portion of the external auditory canal. Fixation was accomplished by immersing the guinea 
pig heads in a 2.5% Gluteraldehyde solution for 5 days. 
 Decalcification was perfomed using a concentrated Plank solution, consisting of 
Aluminum Chloride and Hydrochloric Acid. This solution was changed three times per 
week for two weeks leading up to electron microscopy. 
 Temporal bone dissection was performed at the end of this process. The bone was 
considerably softened and easy to section with a standard 15-gauge scalpel. We began by 
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isolating the temporal bone from the rest of the cranium and soft tissue. Careful 
dissection was required to locate the cochlea and separate it from the temporal bone without 
damaging it. In order to view rows of ciliated hair cells, transverse cuts through the cochlea 
were made. One section was obtained per turn of the cochlea, giving us four specimens to 
analyse from each ear. 
 
Scanning Electron Microscopy 
 These sections of each cochlea were then analyzed with our research center’s 
scanning electron microscope (JEOL JSM-6460LV). All sections were evaluated for 
preservation or destruction of cochlear hair cells. 
 
Statistical Analysis 
 Before beginning our study, we determined the number of animals necessary to find 
a clinically significant difference (10 dB) with sufficient statistical power using the method 
of Snedecor and Cochran(73). 
 To interpret ABR results, we performed a variance analysis with repeated measures. 
Results were compared between groups, ears injected and frequencies at each of three pre-
determined time intervals: before injection, after one series of injections and after two 
series of injections. 
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Results 
 
We excluded one animal from the Nystatin group at the beginning of the study due 
to profound bilateral hearing loss. Eight guinea pigs were male and nine were female, all 
weighing between 257 and 323 grams at the beginning of the experiment. 
 
Auditory Brainstem Response 
Descriptive results: 
After tympanic membrane perforation, mean ABR thresholds among groups ranged 
from 49.3 ± 15.1 dB to 54.3 ± 16.8 dB. After our first set of three injections, we noted a 
similar mild increase in the ABR threshold in all groups, ranging from 57.1 ± 9.4 dB to 
66.3 ± 15.2 dB. At this point we repeated a set of three injections in order to reach a toxic 
level of neomycin. 
A third and final ABR evaluation was completed after the six injections. In Group I, 
similar thresholds were noted when comparing Nystatin-treated ears with our negative 
control group (63.5 ± 11.5 vs. 56.9 ± 8.6 dB). In Group II, the neomycin-treated ears had 
highly increased ABR threshold (93.6 ± 18.1 dB) compared with the control group (64.4 ± 
16.7 dB). All findings are summarized in Table 3 and in Figures 2 and 3(74).  
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Table 3: Auditory Brainstem Response Results 
  
Pre-injection 
threshold (dB) 
Threshold after 
1 set of 
injections (dB) 
Threshold after 
2 sets of 
injections (dB) 
Nystatin 50.5 66.3 63.5 Group 1 
Normal Saline 52.9 57.1 56.9 
Neomycin 54.3 63.6 93.6 Group 2 
Normal Saline 49.3 57.8 64.4 
 
Figure 2: Group I Auditory Brainstem Response 
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Figure 3: Group II Auditory Brainstem Response 
 
 
Statistical Analysis 
Initial analysis was performed using a four-way ANOVA with the following 
independent variables: group (experimental vs. positive control), treatment (Nystatin or 
neomycin vs. normal saline), time (pre-injection, after 1 set of injections, after 2 sets of 
injections) and frequency (2000, 3000, 4000, 6000 and 8000Hz). An interaction between 
the frequency, time and treatment variables (F=2.68, p=0.01) forced us to perform 
independent three-way ANOVA tests for each recorded frequency. These tests did not 
reveal any statistically significant differences of injection product effect between 
frequencies.  
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After having excluded a statistically significant impact of the frequency variable 
on results, we proceeded with a three-way ANOVA with the remaining variables. This test  
revealed an interaction between these variables (F=4.97; p=0.017), leading us to separate 
our analysis into Nystatin and neomycin groups, and perform independent two-way 
ANOVA analyses for each.  
 
Nystatin group: 
We found mean ABR values to be statistically significant in at least one of the measured 
times (F=11.39, p=0.01). A Bonferoni multiple comparison test revealed that pre-injection 
thresholds were better compared to thresholds after two series of injections by an average 
of 10.1 dB (p=0.003). All other thresholds were similar, including comparisons between 
test ears and control ears. 
 
Neomycin group:  
Once again, an interaction was discovered between the time and ear injected variables 
(F=9.17, p=0.02). A Bonferoni multiple comparison test revealed that the only significant 
differences between ears were after 2 series of injections. At this moment, an average 
difference of 29.1 dB (p<0.0001) was found between test ears and control ears 
 
Electron Microscopy 
 The inner ears exposed to physiological saline solution had no discernible hair cell 
loss and were used as a basis for comparison. Neomycin-treated ears demonstrated partial 
to total destruction of all three layers of outer hair cells. Images from the Nystatin group 
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were similar to the negative control group, with preserved outer hair cell architecture. 
Examples of images obtained are shown in Figure 4. 
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Figure 4: Scanning Electron Microscopy 
 
A cochlea exposed to normal saline. Note the three rows of outer hair cells and the row of inner hair 
cells with normal architecture. b Cochlea exposed to neomycin. Note the important outer hair cell 
destruction. c Cochlea exposed to nystatin. Preserved outer hair cell architecture is evident. 
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Discussion 
 
Nystatin 
Successful treatment of otomycosis begins with a correct diagnosis and requires 
proper cleansing of the external ear canal, optimal environmental factors and an effective 
antifungal agent. Recognized risk factors include immunosuppression, recent acute otitis 
media, presence of cerumen and recent use of topical antibiotic and steroid preparations(75). 
Patients will typically complain of otalgia, pruritis, persistant discharge and mild hearing 
loss.   
Evaluation with binocular vision is crucial and therefore all patients should be 
examined with a microscope. Physical exam findings are characteristic and include a 
blotting paper appearance of the matted mycelia and fruiting bodies or conidiphores(76). 
Proper cleansing and drying are necessary to exclude complications such as TM perforation 
or associated middle ear pathology.  Malignant otitis externa can also result from 
otomycosis in immunocompromised individuals, most often when Aspergillus fumigatus is 
responsible(77). 
Topical antimicrobial preparations are the mainstay of otomycosis treatment. The 
ideal topical antifungal should not be ototoxic and should be effective against the most 
commonly isolated organism. Nystatin is macrolid antibiotic agent that exerts its effect by 
inhibiting sterol synthesis and increasing permeability of the cell membrane.(78) It is 
available as ointment and cream preparations, ophthalmic drops, liquid suspension and oral 
pills. Despite previous efforts to demonstrate its safety when exposed to the middle ear, no 
study had thus far excluded its potential for ototoxicity. 
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 Efficacy of Nystatin has been reported in a number of studies. In an in vitro 
study, Lawrence et al. demonstrated that Nystatin has specific anti-fungal activity in 
contrast to Merthiolate and Cresylate, which have non-specific anti-microbial activity(79). In 
a series in Burma, Than et al. reported curing 80% of his patients within a week of 
initiating Nystatin therapy(80). In a series of 411 patients, Paulose et al. found that Nystatin 
was more effective when combined with a steroid or another antimicrobial agent(1). 
Resistance to Nystatin has been reported. In a patient diagnosed with otomycosis induced 
by topical antimicrobials, Jackman reported a case of a patient requiring oral Fluconazole 
after unsuccessful Nystatin treatment(81). Based on clinical experience, Besbes claims that 
Nystatin is the most effective anti-mycotic agent avaible(82). It covers a wide spectrum of 
fungal infections, including the very common Candida and Aspergillus species. Using 15 
species of fungi and yeast, Stern et al. demonstrated in an in vitro study that Nystatin had 
the widest spectrum of activity among antifungals(83). Among the currently used 
antimycotic agents, Nystatin is also the least expensive agent available in our tertiary care 
center. 
 Since no otic Nystatin preparation is currently available, different options must be 
considered. Regular application of ophthalmic drops is an effective solution, but requires 
treatment for at least seven days and efficacy varies with patient compliance. We 
recommend generous application of ointment in a clean external auditory canal or mastoid 
cavity with follow-up at seven days to clean residue and confirm infection resolution. 
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Results analysis 
Our results support the predominant belief that Nystatin is free of ototoxic potential, 
even when exposed directly to the middle ear. When we look at our data in depth, however, 
some of the findings were unexpected.  
Our first observation was that initial ABR recordings yielded thresholds ranging 
from 49.3 to 54.3 dB after TM perforation. Although data for guinea pigs is not available, a 
2005 review of simple TM perforation in children noted possible hearing loss up to 35 dB 
attributable to the perforation(84). Many factors may explain why our observed hearing loss 
was greater. First, the mechanism of perforation was highly traumatic, using a surgical pick 
to tear the TM and an alligator forcep to remove 30 to 50 percent of the TM. Such 
manipulation could potentially cause damage to the underlying ossicles. We considered at 
the beginning of the study placing trans-tympanic ventilation tubes in all animals to 
minimize trauma and perforation closure. We decided against it due to the probable 
difficulty we would experience with tube obstruction. Next, the unit of measure in our 
study is the absolute dB, whereas hearing tests in humans most often utilize hearing level 
dB. Independently of the cause of our findings, they underline the importance of obtaining 
a pre-treatment ABR recording in the setting of such an experiment. 
After our first set of injections, thresholds increased to 57.1 to 66.3 dB, without 
clinically or statistically significant differences between the groups. Despite three 
treatments of neomycin in three weeks, no evidence of significant hearing loss was found. 
Most agree that toxicity level depends on the time of exposure and the dosage, but no clear 
guidelines exist for animal studies. In a study of similar design, Marsh injected anti-
mycotics into guinea pig middle ears and left each substance in place for one hour(7). He 
then obtained ABR recordings one hour later and found significant hearing loss (over 40 
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dB). We hypothesized that the intervals between our injections were too wide, and 
therefore scheduled three more injections at two-day intervals. This strategy was 
presumably responsible for obtaining a toxic level of neomycin, with measured thresholds 
averaging 93.6 dB. 
The use of burst tone stimuli in our ABR testing allowed us to compare the impact 
of injections between frequencies. Theoretically we would have expected neomycin to have 
a greater impact on the higher frequencies, as is known of aminoglycoside toxicity in 
humans. Our results, however, did not support this hypothesis. One possible explanation for 
this finding is that we selectively tested frequencies beginning at 2000 Hz, expecting little 
or no impact in the range of 250 to 1000 Hz. 
 
Pathophysiology of the safety of Nystatin 
In our study, there was no clinically or statistically significant difference between 
the effect of Nystatin and Sodium Chloride on guinea pig ear function. Based on our SEM 
images showing what appears to be Nystatin residue (Figure 3C), which supports Tom’s 
findings, it appears evident that the anti-mycotic is not harmful to OHCs. There is however 
another possibility that deserves special consideration: the Nystatin molecule may not 
penetrate into the cochlea in the first place. Experts agree that the most likely route of 
access to the cochlea from the middle ear is the round window membrane (RWM). This 
membrane is the only soft tissue communication between the two spaces. The permeability 
of the RWM depends on molecular size and configuration, liposolubility, concentration 
gradient and particle electrical charge(85). Much like the tympanic membrane, the RWM is 
composed of two mucous membranes and one central fibrous layer(86). In an experimental  
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guinea pig study, Mikulec demonstrated that factors such as middle ear inflammation and 
suction around the RWM could increase its permeability by a factor of 10-15(87). In 
humans, this membrane is known to be permeable to gentamicin and steroid solutions, as 
they are effective treatments for Menière’s disease and other inner ear pathologies. These 
clinical observations have been confirmed with in vitro experimental studies(88, 89). While 
the molecular weight of gentamicin is 477.6 Da (C21H43N5O7), Nystatin’s is considerably 
greater at 926.1 Da (C47H75NO17). This does not appear to be the limiting factor in this 
case, however, since Chelikh demonstrated that even Inulin (molecular weight 7,000 Da) 
crossed the RWM in guinea pigs after prolonged delivery(90). With these findings 
suggesting that Nystatin does in fact permeate into cochlear perilymph, it is reasonable to 
assume that the molecule itself is not harmful to guinea pig OHCs. 
 
Possible implications in humans 
In a previous section, we discussed some of the differences between human and 
guinea pig anatomy. Though it has never been proven that human ears respond differently 
to ototoxic agents, it is important to consider the variables between the two models before 
extrapolating our results. 
Let us begin by considering the factors that would potentially increase exposure to 
the tested agent in the human. First, the maximum quantity of ointment that can be used in 
a human ear greatly exceeds that of a guinea pig. While we used less than 0.1 cc of Nystatin 
for guinea pigs to fill up their middle ear, the quantity used on an adult patient with a 
mastoid cavity could easily be 10 times greater. Second, our experiment was performed on 
ears that were devoid of infection and consequent inflammation. Goycoolea demonstrated 
that inflammation causes an acute phase of increased RWM permeability followed by 
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fibrosis and decreased diffusion potential in cats(86). These observations were later 
reproduced using neomycin in guinea pigs(91). In humans with acute otomycosis, it would 
be possible for inflammation to extend to the middle ear and temporarily increase RWM 
permeability. Finally, Ghiz found the average surface area of this membrane in guinea pigs 
to be 1.18 mm2, compared with 2.98 mm2 found in humans by Takahashi(92, 93). 
 A strong argument can also be made for less Nystatin reaching the perilymph in a 
context of otomycosis in humans. First and foremost, Nystatin application in humans is 
topical in the external auditory canal. Even in the presence of a TM perforation or a 
ventilation tube, the actual quantity of product exposed to the middle ear would range from 
negligible to moderate. In our study, we deliberately filled the middle ear space with 
ointment and left it in place for several weeks. Also, two anatomical factors protect the 
human OHCs better than guinea pigs: a thicker RWM and a deeper and less accessible 
round window niche. Average human RWM thickness is 5 to 6 times that of the guinea pig 
and in 70% of cases is covered by mucosal folds, or a “false round window membrane”, 
further protecting the cochlea(5). The depth of the round window niche in humans is 
variable and acts as another anatomical barrier to ototoxic agents(39). 
 General consensus among experts is that human OHCs are more protected than their 
guinea pig counterparts, but further studies confirming this belief for the Nystatin molecule 
are necessary. 
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Study limits and future outlook  
Electron microscopy: 
 Our greatest challenge for this study was obtaining consistent images of the organ 
of Corti allowing us to evaluate OHC architecture at every level of the cochlea. The 
principal problem was unpredictable tectorial membrane adhesion. Though different 
preparation techniques have been described, none seem to address this problem 
specifically. A recent study published in May 2011 describes a new technique whereby the 
RWN is perforated and perfused with 2% gluteraldehyde in a phosphate-buffered solution 
(PBS), and subsequently perfused with 1% osmium tetroxyde(94). Exposure of the organ of 
Corti was obtained by lateral wall dissection and therefore did not depend on tectorial 
membrane removal. Though much more complex and time-consuming, this technique 
yielded impressive images and is well worth attempting. With such evolving techniques 
and higher resolution microscopes, it will be possible to evaluate the ototoxic potential of 
antibiotics and other agents in much greater detail. 
 
Auditory Brainstem Response: 
 As previously discussed, auditory brainstem response appears to be the most 
reliable tool to evaluate hearing function in animals. This technique, however, remains far 
from ideal.  It is a device designed for use in human beings with our relatively limited 
frequency range. What would we observe if we tested ototoxic agents in guinea pigs in 
frequencies as high as 40 or 50 kHz instead of stopping at 8 kHz? Would those results have 
any implications in humans? An argument could be made that our equipment does not  
evaluate the entire basal turn of the guinea pig cochlea. A second limitation with our ABR 
testing was the environment in which the tests were carried out, which was not up to the 
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standards of human testing. The animal care center in which tests were performed was 
quiet but not soundproof. Other instruments in the surrounding environment caused visible 
interference, which may have potentially influenced our results. Future studies correlating 
ABR results with histological findings may lead to specific parameters for animal testing, 
thereby increasing the internal and external validity of these studies. 
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Conclusion 
Nystatin is a large-spectrum and inexpensive anti-mycotic agent effective in the 
treament of otomycosis. Its direct application in the middle ear of guinea pigs does not 
influence inner ear function as measured by auditory brainstem response, nor does it affect 
cochlear outer cell hair architecture observed with a scanning electron microscope. Further 
studies will be required to confirm Nystatin as a safe option for treatment of otomycosis in 
presence of a ventilation tube or tympanic membrane perforation in humans. 
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